SCHEMBL63492

SCHEMBL63492

Cc1cc(CNC(=O)c2nc3n(c(=O)c2O)CC2CCC3(N(C)C(=O)c3cccnc3)CC2)ccc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
KCNH2 Q12809 1/20 0.37
CYP2C9 P11712 1/20 0.37
TLR2 O60603 1/20 0.36
HPGD P15428 1/20 0.35
MMP13 P45452 3/20 0.34
TSHR P16473 2/20 0.34
USP2 O75604 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NPC1 O15118 1/20 0.34
WDR5 P61964 1/20 0.34
PIK3CD O00329 1/20 0.34
NAMPT P43490 2/20 0.33
EED O75530 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63496 0.91 KCNH2 (0.46) KCNH2CYP2C9TLR2TSHRUSP2
SCHEMBL64216 0.88 HCRTR1 (0.39) HCRTR1HCRTR2KCNH2CYP2C9TLR2
SCHEMBL51612 0.86 CYP2C9 (0.47) KCNH2CYP2C9MMP13WDR5
SCHEMBL87417 0.83 CYP2C9 (0.44) KCNH2CYP2C9MMP13
SCHEMBL63480 0.82 KCNH2 (0.48) KCNH2CYP2C9NAMPTKMT2A
SCHEMBL63867 0.82 NAMPT (0.40) HCRTR1HCRTR2KCNH2CYP2C9TLR2
SCHEMBL53150 0.82 CYP2C9 (0.39) KCNH2CYP2C9MMP13
SCHEMBL52304 0.82 CYP2C9 (0.40) KCNH2CYP2C9MMP13WDR5
SCHEMBL52672 0.80 CYP2C9 (0.48) KCNH2CYP2C9MMP13NAMPT
SCHEMBL52457 0.80 CYP2C9 (0.37) KCNH2CYP2C9MMP13TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG HCRTR1 4797/4885HCRTR2 4835/4885KCNH2 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.